About Casein kinase II subunit alpha'
Casein kinase II subunit alpha' (CSNK2A2) is a protein
from Homo sapiens identified by UniProt accession
P19784, 350 residues long.
MolForge cross-references it against 0 known binders and
191 disease associations.
Target properties
| Protein name | Casein kinase II subunit alpha' |
| UniProt accession | P19784 |
| Gene | CSNK2A2 |
| Organism | Homo sapiens |
| Length | 350 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (15)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (191)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.39
- neuroinflammatory disorder · score 0.32
- Parkinson disease · score 0.32
- Alzheimer disease · score 0.32
- lysosomal storage disease · score 0.32
- multiple sclerosis · score 0.32
- breast adenocarcinoma · score 0.27
- head and neck squamous cell carcinoma · score 0.25
- endometrial cancer · score 0.25
- telomere length · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P19784-F1 | alphafold | PREDICTED | 94.14 | — |
Amino-acid sequence (350 residues)
MPGPAAGSRA RVYAEVNSLR SREYWDYEAH VPSWGNQDDY QLVRKLGRGK YSEVFEAINI TNNERVVVKI LKPVKKKKIK REVKILENLR GGTNIIKLID TVKDPVSKTP ALVFEYINNT DFKQLYQILT DFDIRFYMYE LLKALDYCHS KGIMHRDVKP HNVMIDHQQK KLRLIDWGLA EFYHPAQEYN VRVASRYFKG PELLVDYQMY DYSLDMWSLG CMLASMIFRR EPFFHGQDNY DQLVRIAKVL GTEELYGYLK KYHIDLDPHF NDILGQHSRK RWENFIHSEN RHLVSPEALD LLDKLLRYDH QQRLTAKEAM EHPYFYPVVK EQSQPCADNA VLSSGLTAAR
Explore Casein kinase II subunit alpha' with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets